Concepts (86)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mobile Applications | 2 | 2025 | 108 | 0.380 |
Why?
|
| Self-Management | 2 | 2025 | 111 | 0.370 |
Why?
|
| Asthma | 2 | 2025 | 895 | 0.230 |
Why?
|
| Cancer Vaccines | 1 | 2025 | 188 | 0.210 |
Why?
|
| Dendritic Cells | 1 | 2025 | 435 | 0.190 |
Why?
|
| Atrial Septum | 1 | 2022 | 19 | 0.180 |
Why?
|
| Glioblastoma | 1 | 2025 | 331 | 0.180 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2022 | 296 | 0.150 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2022 | 269 | 0.150 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 22 | 0.140 |
Why?
|
| Febuxostat | 1 | 2018 | 21 | 0.140 |
Why?
|
| Azithromycin | 1 | 2018 | 43 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 541 | 0.140 |
Why?
|
| Allopurinol | 1 | 2018 | 77 | 0.130 |
Why?
|
| Medicine | 1 | 2018 | 100 | 0.130 |
Why?
|
| Veterans Health | 1 | 2018 | 171 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2022 | 776 | 0.120 |
Why?
|
| Brain Neoplasms | 1 | 2025 | 1224 | 0.120 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 227 | 0.120 |
Why?
|
| Gout | 1 | 2018 | 170 | 0.110 |
Why?
|
| Meningitis, Bacterial | 1 | 2015 | 96 | 0.100 |
Why?
|
| Sulfasalazine | 1 | 2013 | 4 | 0.100 |
Why?
|
| Hydroxychloroquine | 1 | 2013 | 19 | 0.100 |
Why?
|
| Pneumococcal Vaccines | 1 | 2015 | 174 | 0.100 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2013 | 73 | 0.100 |
Why?
|
| Pneumococcal Infections | 1 | 2015 | 278 | 0.090 |
Why?
|
| Antirheumatic Agents | 1 | 2013 | 118 | 0.090 |
Why?
|
| Methotrexate | 1 | 2013 | 313 | 0.090 |
Why?
|
| Bacteremia | 1 | 2015 | 420 | 0.080 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 773 | 0.080 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2013 | 285 | 0.080 |
Why?
|
| Middle Aged | 7 | 2025 | 27789 | 0.070 |
Why?
|
| Adult | 7 | 2025 | 30513 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2519 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 1203 | 0.060 |
Why?
|
| Mycobacterium ulcerans | 1 | 2005 | 3 | 0.060 |
Why?
|
| Skin Ulcer | 1 | 2005 | 31 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2025 | 12563 | 0.060 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2005 | 45 | 0.060 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2025 | 203 | 0.050 |
Why?
|
| Male | 8 | 2025 | 62767 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2025 | 398 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2022 | 36 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2018 | 1596 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2025 | 1495 | 0.050 |
Why?
|
| Young Adult | 3 | 2025 | 9693 | 0.040 |
Why?
|
| Aged | 4 | 2025 | 20414 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2022 | 8363 | 0.040 |
Why?
|
| Morbidity | 1 | 2022 | 250 | 0.040 |
Why?
|
| Humans | 10 | 2025 | 127201 | 0.040 |
Why?
|
| Female | 7 | 2025 | 68579 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2022 | 371 | 0.040 |
Why?
|
| Telemedicine | 1 | 2025 | 489 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 489 | 0.040 |
Why?
|
| Equivalence Trials as Topic | 1 | 2018 | 21 | 0.040 |
Why?
|
| Medication Therapy Management | 1 | 2018 | 22 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2022 | 6685 | 0.030 |
Why?
|
| Uric Acid | 1 | 2018 | 109 | 0.030 |
Why?
|
| United States | 3 | 2018 | 11360 | 0.030 |
Why?
|
| Gout Suppressants | 1 | 2018 | 74 | 0.030 |
Why?
|
| Critical Care | 1 | 2022 | 669 | 0.030 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 86 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 5139 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2018 | 274 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 2891 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1596 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2018 | 692 | 0.030 |
Why?
|
| Infant | 3 | 2018 | 12801 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2018 | 14444 | 0.030 |
Why?
|
| Etanercept | 1 | 2013 | 44 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2013 | 336 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 752 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1270 | 0.020 |
Why?
|
| Adolescent | 3 | 2018 | 20135 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2022 | 3072 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 1147 | 0.020 |
Why?
|
| Child | 3 | 2018 | 25277 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 3260 | 0.020 |
Why?
|
| Ghana | 1 | 2005 | 20 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 2996 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 17043 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2005 | 313 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2005 | 1216 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 1382 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2005 | 3325 | 0.010 |
Why?
|
| Risk Factors | 1 | 2005 | 10602 | 0.010 |
Why?
|